Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
January 19, 2024
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features
Michal Juraska, Hongjun Bai, Allan C deCamp, et al.
Nature Medicine
|
January 16, 2018
Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine
Scott G Hansen, Daniel E Zak, Guangwu Xu, et al.
Mbio
|
September 9, 2025
Bayesian estimation of HIV acquisition dates for prevention trials
Raabya Rossenkhan, Elena E Giorgi, Danica Shao, et al.
Ebiomedicine
|
June 10, 2023
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
Kelly E Seaton, Yunda Huang, Shelly Karuna, et al.
Nature
|
September 11, 2012
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
Morgane Rolland, Paul T Edlefsen, Brendan B Larsen, et al.
Nature Medicine
|
August 22, 2022
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
Peter B Gilbert, Yunda Huang, Allan C deCamp, et al.
Plos One
|
November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
Nature Communications
|
April 3, 2026
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials
Carolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Biorxiv : the Preprint Server for Biology
|
July 17, 2025
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials
Carolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Journal of Virology
|
May 16, 2014
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial
Andrew J Gartland, Sue Li, John McNevin, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
Proceedings of the National Academy of Sciences of the United States of America
|
January 19, 2024
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features
Michal Juraska, Hongjun Bai, Allan C deCamp, et al.
Nature Medicine
|
January 16, 2018
Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine
Scott G Hansen, Daniel E Zak, Guangwu Xu, et al.
Mbio
|
September 9, 2025
Bayesian estimation of HIV acquisition dates for prevention trials
Raabya Rossenkhan, Elena E Giorgi, Danica Shao, et al.
Ebiomedicine
|
June 10, 2023
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
Kelly E Seaton, Yunda Huang, Shelly Karuna, et al.
Nature
|
September 11, 2012
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
Morgane Rolland, Paul T Edlefsen, Brendan B Larsen, et al.
Nature Medicine
|
August 22, 2022
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
Peter B Gilbert, Yunda Huang, Allan C deCamp, et al.
Plos One
|
November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
Nature Communications
|
April 3, 2026
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials
Carolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Biorxiv : the Preprint Server for Biology
|
July 17, 2025
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials
Carolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Journal of Virology
|
May 16, 2014
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial
Andrew J Gartland, Sue Li, John McNevin, et al.
Page
of 9